Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats

Gut

Volumn 64, Issue 4, 2015, Pages 657-666

  Mejias, Marc ^a   Coch, Laura ^a   Berzigotti, Annalisa ^a   Garcia Pras, Ester ^a   Gallego, Javier ^a   Bosch, Jaime ^a   Fernandez, Mercedes ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MESSENGER RNA; METALLOPROTEINASE; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; VASCULOTROPIN; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EXPRESSION VECTOR; FIBRINOLYSIS; FIBROGENESIS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; MALE; MESENTERY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PEDF GENE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; RAT MODEL; RISK REDUCTION; SHAM PROCEDURE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BILE DUCT; HYPERTENSION, PORTAL; LIGATION; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BILE DUCTS; EYE PROTEINS; HUMANS; HYPERTENSION, PORTAL; LIGATION; LIVER CIRRHOSIS; MALE; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SERPINS;

EID: 84924420610     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307138     Document Type: Article

References (40)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
2. Sanyal AJ, Bosch J, Blei A, et al. Portal hypertension and its complications. Gastroenterology 2008;134:1715-28.
3. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823-32.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
5. Mejias M, Garcia-Pras E, Tiani C, et al. Benefi cial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245-56.
6. Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009;50:604-20.
7. Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology 2009;49:1066-8.
8. Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol 2009;27:833-5.
9. Pinter M, Sieghart W, Reiberger T, et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma. A pilot study. Aliment Pharmacol Ther 2012;35:83-91.
10. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
11. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin PEDF: new insights into phylogeny, function, and signaling. Front Biosci 2005;10:2131-49.
12. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 2003;9:244-50.
13. Amaral J, Becerra S. Pigment epithelium-derived factor and angiogenesis: therapeutic implications . Dordrecht, The Nederlands: Springer, 2008:311-37.
14. Wang B, Atherton P, Patel R, et al. Antiangiogenic effects and transcriptional regulation of pigment epithelium-derived factor in diabetic retinopathy. Microvasc Res 2010;80:31-6.
15. Wang JJ, Zhang SX, Mott R, et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy. Evidence for antifibrogenic activities. Diabetes 2006;55:1678-85.
16. Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 2009;13:1295-302.
17. Matsumoto K, Ishikawa H, Nishimura D, et al. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004;40:252-9.
18. Ek ETH, Dass CR, Choong PFM. PEDF: a potential molecular therapeutic target with multiple anticancer activities. Trends Mol Med 2006;12:497-502.
19. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003;4:628-36.
20. Tombran-Tink J, Mazuruk K, Rodriguez IR, et al . Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol Vis 1996;2:11.
21. Ho TC, Chen SL, Shih SC, et al. Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells. Am J Pathol 2010;177:1798-811.
22. Coch L, Mejias M, Berzigotti A, et al. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology Published Online First: 4 Jan 2014. doi:10.1002/hep.26995
23. Berzigotti A, Abraldes JG, Tandon P, et al. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol 2010;52:846-53.
24. Bernard A, Gao-Li J, Franco CA, et al. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 2009;284:10480-90.
25. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69.
26. Takenaka K, Yamagishi S, Jinnouchi Y, et al. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005;77:3231-41.
27. Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006;37:1-12.
28. Hennenberg M, Trebicka J, Kohistani Z, et al. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest 2011;91:241-51.
29. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76.
30. Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 2004;137:668-74.
31. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 2006;82:99-110.
32. Ogata N, Matsuoka M, Matsuyama K, et al. Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab 2007;92:1176-9.
33. Matsuoka M, Ogata N, Minamino K, et al. High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes. Exp Eye Res 2006;82:172-8.
34. Miyagishi D, Ohno-Matsui K, Amagasa T, et al. Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines. Cancer Lett 2003;196:77-85.
35. Ohno-Matsui K, Yoshida T, Uetama T, et al. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 2003;303:962-7.
36. Yamagishi S, Adachi H, Abe A, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006;91:2447-50.
37. Kuncl RW, Bilak MM, Bilak SR, et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J Neurochem 2002;81:178-84.
38. Crawford SE, Stellmach V, Ranalli M, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001;114:4421-8.
39. Crawford SE. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9:774-80.
40. Kawaguchi T, Yamagishi S, Itou M, et al. Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells. Am J Pathol 2010;176:168-76.